HC Wainwright Has Bearish Forecast for VIR FY2029 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Equities researchers at HC Wainwright cut their FY2029 earnings estimates for Vir Biotechnology in a research note issued to investors on Friday, January 31st. HC Wainwright analyst P. Trucchio now expects that the company will earn $2.25 per share for the year, down from their previous estimate of $2.56. HC Wainwright currently has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share.

Several other research firms have also commented on VIR. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. JPMorgan Chase & Co. increased their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Leerink Partners lifted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. Finally, Barclays lowered their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Stock Performance

VIR stock opened at $9.98 on Monday. The company has a market capitalization of $1.37 billion, a PE ratio of -2.55 and a beta of 0.63. Vir Biotechnology has a one year low of $6.56 and a one year high of $14.45. The company’s 50 day moving average price is $8.86 and its two-hundred day moving average price is $8.50.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 15.60% of the stock is owned by insiders.

Institutional Trading of Vir Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of VIR. Blue Trust Inc. boosted its holdings in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after purchasing an additional 2,351 shares during the last quarter. nVerses Capital LLC purchased a new position in Vir Biotechnology in the third quarter worth about $56,000. KBC Group NV grew its stake in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Vir Biotechnology during the 4th quarter valued at about $74,000. Finally, Captrust Financial Advisors bought a new position in shares of Vir Biotechnology in the 3rd quarter worth approximately $118,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).